| Identification | Back Directory | [Name]
Propanoic acid, 2-[[(2,4,5,7-tetranitro-9H-fluoren-9-ylidene)amino]oxy]-, (4S)-10-[(dimethylamino)methyl]-4-ethyl-3,4,12,14-tetrahydro-9-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester | [CAS]
1432468-79-5 | [Synonyms]
TLC388
TLC-388
TLC 388
Propanoic acid, 2-[[(2,4,5,7-tetranitro-9H-fluoren-9-ylidene)amino]oxy]-, (4S)-10-[(dimethylamino)methyl]-4-ethyl-3,4,12,14-tetrahydro-9-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester | [Molecular Formula]
C39H30N8O15 | [MOL File]
1432468-79-5.mol | [Molecular Weight]
850.7 |
| Hazard Information | Back Directory | [Uses]
TLC388 is a novel camptothecin analog with limited antitumor activity in metastatic NEC[1]. | [References]
[1] Ming-Huang Chen, et al. An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas. Oncologist. 2020 May;25(5):e782-e788. DOI:10.1634/theoncologist.2019-0490 |
|
|